An ethical assessment of compounded bioidentical hormone therapy
Authors:
- 30 January 2024
- journal article
- research article
- Published by Taylor & Francis in Climacteric
- Vol. 27 (3) , 326-328
Abstract
The use of compounded bioidentical hormone therapy (cBHT) continues to grow in popularity despite the availability of many US Food and Drug Administration-approved hormone products produced in different formulations and dosages. Numerous claims made by proponents of cBHT are not substantiated by properly designed studies. Valid concerns about purity, efficacy, bioavailability and safety of cBHT have been raised. Since patient welfare is the first duty of health professionals, promoting and prescribing cBHT as first-line therapy violates a number of ethical tenets of medical and pharmacy practice and should be discouraged without a compelling reason.Keywords
This publication has 18 references indexed in Scilit:
- Custom-compounded bioidentical hormone therapy: why so popular despite potential harm? The case against routine useClimacteric, 2017
- How Should Therapeutic Decisions about Expensive Drugs Be Made in Imperfect Environments?AMA Journal of Ethics, 2017
- Hormone-replacement therapy: current thinkingNature Reviews Endocrinology, 2016
- Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific StatementThe Journal of Clinical Endocrinology & Metabolism, 2016
- What are the concerns about custom-compounded “bioidentical” hormone therapy?Menopause, 2014
- Why Physicians Should Not Lie for Their PatientsThe American Journal of Bioethics, 2012
- Bioidentical hormone therapy: a panacea that lacks supportive evidenceCurrent Opinion in Obstetrics and Gynecology, 2008
- Ethical problems with bioidentical hormone therapyInternational Journal Of Impotence Research, 2007
- Patient-centredness: a conceptual framework and review of the empirical literatureSocial Science & Medicine, 2000
- The advertising of doctors' services.Journal of Medical Ethics, 1991